trial · primary record
Datopotamab Deruxtecan
Non-Small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 675 |
| Primary completion | 2029-12-28 |
| Primary endpoint | Progression-Free Survival (PFS) in TROP2 biomarker positive participants. |
| Registry ID | NCT06357533 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:28.412Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06357533
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Datopotamab Deruxtecan · compound